Kininogen-1
| GO Term |
|---|
| signaling receptor binding |
| heparin binding |
| zinc ion binding |
| cysteine-type endopeptidase inhibitor activity |
| hormone activity |
| Position | Description |
|---|---|
| 48 | Not glycosylated |
| Position | Description | PubMed ID | GlyTouCan ID | Source |
|---|---|---|---|---|
| 533 | O-linked (GalNAc...) threonine | |||
| 542 |
|
|||
| 546 | O-linked (GalNAc...) threonine | |||
| 550 |
|
|||
| 557 |
|
|
||
| 571 |
|
|||
| 577 |
|
|||
| 599 |
|
|||
| 604 |
|
|||
| 621 |
|
| Pathway Name | Organism |
|---|---|
| G alpha (i) signalling events | Homo sapiens |
| G alpha (q) signalling events | Homo sapiens |
| Intrinsic Pathway of Fibrin Clot Formation | Homo sapiens |
| Peptide ligand-binding receptors | Homo sapiens |
| Platelet degranulation | Homo sapiens |
| Post-translational protein phosphorylation | Homo sapiens |
| Regulation of IGF Activity by IGFBP | Homo sapiens |
| DO ID | Disease Name | Source |
|---|---|---|
| DOID:0111676 | high molecular weight kininogen deficiency | |
| DOID:14735 | hereditary angioedema |
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.4.0
Last updated: December 8, 2025